Herold KC, et al. - Via conducting a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab on 76 participants with type 1 diabetes, researchers intended determined the interventions that could affect clinical progression of type 1 diabetes before diagnosis would be needed. Expected adverse events were rash and transient lymphopenia. Among the participants who were HLA-DR3–negative, HLA-DR4–positive, or anti–zinc transporter 8 antibody–negative, fewer participants in the teplizumab vs placebo group had diabetes diagnosed. The authors, therefore, concluded that delayed progression to clinical type 1 diabetes in high-risk participants could be achieved with teplizumab.